Drug Trial Radar · NCT07943078
A Study of JNJ-99220732 in Participants With Advanced or Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Jan 5, 2029
Study completion Jan 16, 2030
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out how safe and well-tolerated JNJ-99220732 is and to find out the most suitable dose (\[putative\] recommended phase 2 dose \[pRP2D\] regimen\[s\]) of JNJ-99220732 (Part 1-Dose Escalation). Also, to find out how safe and well-tolerated JNJ-99220732 is at the pRP2D regimen(s) as determined in Part 1 (Part 2- Dose Expansion).
Conditions
- Neoplasms
Interventions
JNJ-99220732Drug
JNJ-99220732 will be administered intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AE) by SeverityTime frame: Up to 3 years 2 months
- Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)Time frame: Up to 21 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.